Ribo und Madrigal erreichen ersten wichtigen Meilenstein bei der Weiterentwicklung neuartiger siRNA-Therapien für MASH

PartnershipPositive

AI Analysis

Summary

Ribo and Madrigal Pharmaceuticals announced the achievement of the first major milestone in their collaboration to develop novel siRNA therapies for MASH (metabolic dysfunction-associated steatohepatitis).

Outcome Details

First important milestone achieved in collaboration

Importance:6/10

Sentiment:

0.50

siRNAMASHPartnershipCollaborationDrug Development

Related Companies

$06938.HK $MDGL

Read the original article

Published by PR Newswire Biotech on July 2, 2026 2:53 PM

Read Original